ZYME
Zymeworks Inc.
Biotechnology · Healthcare · United States
28.71
close · 2026-10-29
value
14
cheaper than peers14
quality
9
stronger fundamentals9
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 23.63× | 43 |
| price to sales | 46.18× | 26 |
| price to book | 25.52× | 7 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 19.9% | 49 |
| return on equity | -72.3% | 35 |
| operating margin | -919.0% | 23 |
| revenue growth | -90.6% | 5 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$65.1M |
| employees | 231 |
| first trade | 2017-04-28 |
| next earnings | 2026-11-09 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.08 | -1.62 | -1.72 | 1.90 |
| free cash flow | -$35.4M | -$113.1M | -$122.4M | $131.0M |
| net income | -$81.1M | -$122.7M | -$118.7M | $124.3M |
| revenue | $106.0M | $76.3M | $76.0M | $412.5M |
| unusual items | -$610,000 | -$16.5M | -$1.2M | $1.2M |